cambridge pharma consultancy limited
cambridge pharma consultancy limited Company Information
Company Number
02297716
Website
https://www.imshealth.comRegistered Address
3 forbury place, 23 forbury road, reading, RG1 3JH
Industry
Non-trading company
Telephone
-
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
iqvia ltd. 100%
cambridge pharma consultancy limited Estimated Valuation
Pomanda estimates the enterprise value of CAMBRIDGE PHARMA CONSULTANCY LIMITED at £0 based on a Turnover of £0 and 0.44x industry multiple (adjusted for size and gross margin).
cambridge pharma consultancy limited Estimated Valuation
Pomanda estimates the enterprise value of CAMBRIDGE PHARMA CONSULTANCY LIMITED at £0 based on an EBITDA of £0 and a 3.85x industry multiple (adjusted for size and gross margin).
cambridge pharma consultancy limited Estimated Valuation
Pomanda estimates the enterprise value of CAMBRIDGE PHARMA CONSULTANCY LIMITED at £0 based on Net Assets of £0 and 2.08x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Cambridge Pharma Consultancy Limited Overview
Cambridge Pharma Consultancy Limited is a live company located in reading, RG1 3JH with a Companies House number of 02297716. It operates in the non-trading company sector, SIC Code 74990. Founded in September 1988, it's largest shareholder is iqvia ltd. with a 100% stake. Cambridge Pharma Consultancy Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Cambridge Pharma Consultancy Limited Health Check
There is insufficient data available to calculate a health check for Cambridge Pharma Consultancy Limited. Company Health Check FAQs
0 Strong
0 Regular
0 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Cambridge Pharma Consultancy Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Cambridge Pharma Consultancy Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- Cambridge Pharma Consultancy Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- Cambridge Pharma Consultancy Limited
- - Industry AVG
Employees
There is insufficient data available for this Key Performance Indicator!
- - Cambridge Pharma Consultancy Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Cambridge Pharma Consultancy Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Cambridge Pharma Consultancy Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Cambridge Pharma Consultancy Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Cambridge Pharma Consultancy Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Cambridge Pharma Consultancy Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Cambridge Pharma Consultancy Limited
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Cambridge Pharma Consultancy Limited
- - Industry AVG
CAMBRIDGE PHARMA CONSULTANCY LIMITED financials
Cambridge Pharma Consultancy Limited's latest turnover from December 2022 is estimated at 0 and the company has net assets of 0. According to their latest financial statements, we estimate that Cambridge Pharma Consultancy Limited has no employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 18,260,000 | 16,380,000 | 16,150,000 | 13,815,000 | 15,051,000 | 14,498,000 | 13,352,000 | 13,813,000 | ||||||
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Cost Of Sales | 11,623,000 | 10,800,000 | 9,371,000 | 10,669,000 | 10,316,000 | 9,456,000 | 9,481,000 | 7,790,000 | ||||||
| Gross Profit | 6,637,000 | 5,580,000 | 6,779,000 | 3,146,000 | 4,735,000 | 5,042,000 | 3,871,000 | 6,023,000 | ||||||
| Admin Expenses | 2,184,000 | 2,453,000 | 2,533,000 | 2,417,000 | 2,649,000 | 2,465,000 | 3,457,000 | 3,496,000 | ||||||
| Operating Profit | 4,453,000 | 3,127,000 | 4,246,000 | 729,000 | 2,086,000 | 2,577,000 | 414,000 | 2,527,000 | ||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Interest Receivable | 332,000 | 296,000 | 229,000 | 220,000 | 113,000 | 80,000 | 108,000 | 95,000 | ||||||
| Pre-Tax Profit | 4,785,000 | 3,423,000 | 4,475,000 | 949,000 | 2,199,000 | 2,657,000 | 522,000 | 2,622,000 | ||||||
| Tax | -993,000 | -681,000 | -845,000 | -285,000 | 25,000 | -8,000 | -14,000 | -1,000 | ||||||
| Profit After Tax | 3,792,000 | 2,742,000 | 3,630,000 | 664,000 | 2,224,000 | 2,649,000 | 508,000 | 2,621,000 | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Profit | 3,792,000 | 2,742,000 | 3,630,000 | 664,000 | 2,224,000 | 2,649,000 | 508,000 | 2,621,000 | ||||||
| Employee Costs | 0 | 0 | 3,952,000 | 4,192,000 | 3,845,000 | 5,929,000 | 4,040,000 | 4,524,000 | 4,409,000 | 3,995,000 | ||||
| Number Of Employees | 20 | 36 | 40 | 43 | 45 | 50 | 50 | 53 | ||||||
| EBITDA* | 4,490,000 | 3,171,000 | 4,299,000 | 795,000 | 2,192,000 | 2,632,000 | 455,000 | 2,594,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 61,000 | 93,000 | 113,000 | 138,000 | 134,000 | 194,000 | 121,000 | 93,000 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49,000 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 61,000 | 93,000 | 113,000 | 138,000 | 134,000 | 243,000 | 121,000 | 93,000 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 257,000 | 375,000 | 615,000 | 1,220,000 | 1,998,000 | 3,811,000 | 2,365,000 | 2,918,000 |
| Group Debtors | 0 | 0 | 64,906,000 | 64,906,000 | 0 | 0 | 33,814,000 | 25,709,000 | 22,096,000 | 16,350,000 | 16,599,000 | 11,234,000 | 7,662,000 | 7,443,000 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 314,000 | 342,000 | 350,000 | 529,000 | 919,000 | 465,000 | 447,000 | 272,000 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 20,000 | 40,000 | 444,000 | 949,000 | 718,000 | 640,000 | 2,317,000 | 942,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 0 | 0 | 64,906,000 | 64,906,000 | 0 | 0 | 34,405,000 | 26,466,000 | 23,505,000 | 19,048,000 | 20,234,000 | 16,150,000 | 12,791,000 | 11,575,000 |
| total assets | 0 | 0 | 64,906,000 | 64,906,000 | 0 | 0 | 34,466,000 | 26,559,000 | 23,618,000 | 19,186,000 | 20,368,000 | 16,393,000 | 12,912,000 | 11,668,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 235,000 | 137,000 | 152,000 | 62,000 | 43,000 | 67,000 | 132,000 | 181,000 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 5,773,000 | 2,680,000 | 2,599,000 | 1,908,000 | 3,566,000 | 1,155,000 | 1,338,000 | 562,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 3,004,000 | 2,126,000 | 1,987,000 | 1,943,000 | 2,347,000 | 3,025,000 | 1,960,000 | 1,908,000 |
| total current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 9,012,000 | 4,943,000 | 4,738,000 | 3,913,000 | 5,956,000 | 4,247,000 | 3,430,000 | 2,651,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 9,012,000 | 4,943,000 | 4,738,000 | 3,913,000 | 5,956,000 | 4,247,000 | 3,430,000 | 2,651,000 |
| net assets | 0 | 0 | 64,906,000 | 64,906,000 | 0 | 0 | 25,454,000 | 21,616,000 | 18,880,000 | 15,273,000 | 14,412,000 | 12,146,000 | 9,482,000 | 9,017,000 |
| total shareholders funds | 0 | 0 | 64,906,000 | 64,906,000 | 0 | 0 | 25,454,000 | 21,616,000 | 18,880,000 | 15,273,000 | 14,412,000 | 12,146,000 | 9,482,000 | 9,017,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 4,453,000 | 3,127,000 | 4,246,000 | 729,000 | 2,086,000 | 2,577,000 | 414,000 | 2,527,000 | ||||||
| Depreciation | 0 | 0 | 0 | 0 | 37,000 | 44,000 | 53,000 | 66,000 | 106,000 | 55,000 | 41,000 | 67,000 | ||
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Tax | -993,000 | -681,000 | -845,000 | -285,000 | 25,000 | -8,000 | -14,000 | -1,000 | ||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 0 | -64,906,000 | 0 | 64,906,000 | 0 | -34,385,000 | 7,959,000 | 3,365,000 | 4,962,000 | -1,417,000 | 3,957,000 | 5,085,000 | -159,000 | 10,633,000 |
| Creditors | 0 | 0 | 0 | 0 | 0 | -235,000 | 98,000 | -15,000 | 90,000 | 19,000 | -24,000 | -65,000 | -49,000 | 181,000 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | -3,004,000 | 878,000 | 139,000 | 44,000 | -404,000 | -678,000 | 1,065,000 | 52,000 | 1,908,000 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -3,486,000 | -751,000 | -1,374,000 | 1,542,000 | -2,442,000 | -1,461,000 | 603,000 | -5,951,000 | ||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | -5,773,000 | 3,093,000 | 81,000 | 691,000 | -1,658,000 | 2,411,000 | -183,000 | 776,000 | 562,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 332,000 | 296,000 | 229,000 | 220,000 | 113,000 | 80,000 | 108,000 | 95,000 | ||||||
| cash flow from financing | 3,471,000 | 371,000 | 897,000 | -1,241,000 | 2,566,000 | -88,000 | 841,000 | 7,053,000 | ||||||
| cash and cash equivalents | ||||||||||||||
| cash | 0 | 0 | 0 | 0 | 0 | -20,000 | -20,000 | -404,000 | -505,000 | 231,000 | 78,000 | -1,677,000 | 1,375,000 | 942,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | -20,000 | -20,000 | -404,000 | -505,000 | 231,000 | 78,000 | -1,677,000 | 1,375,000 | 942,000 |
cambridge pharma consultancy limited Credit Report and Business Information
Cambridge Pharma Consultancy Limited Competitor Analysis
Perform a competitor analysis for cambridge pharma consultancy limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
cambridge pharma consultancy limited Ownership
CAMBRIDGE PHARMA CONSULTANCY LIMITED group structure
Cambridge Pharma Consultancy Limited has no subsidiary companies.
Ultimate parent company
IQVIA HOLDINGS INC
#0013898
2 parents
CAMBRIDGE PHARMA CONSULTANCY LIMITED
02297716
cambridge pharma consultancy limited directors
Cambridge Pharma Consultancy Limited currently has 2 directors. The longest serving directors include Mr Timothy Sheppard (Jun 2022) and Mr James Berkshire (Jun 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Timothy Sheppard | England | 53 years | Jun 2022 | - | Director |
| Mr James Berkshire | United Kingdom | 50 years | Jun 2022 | - | Director |
P&L
December 2022turnover
0
0%
operating profit
0
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
0
0%
total assets
0
0%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
cambridge pharma consultancy limited company details
company number
02297716
Type
Private limited with Share Capital
industry
74990 - Non-trading company
incorporation date
September 1988
age
36
accounts
Dormant
ultimate parent company
previous names
todmarsh limited (December 1988)
incorporated
UK
address
3 forbury place, 23 forbury road, reading, RG1 3JH
last accounts submitted
December 2022
cambridge pharma consultancy limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 7 charges/mortgages relating to cambridge pharma consultancy limited. Currently there are 2 open charges and 5 have been satisfied in the past.
cambridge pharma consultancy limited Companies House Filings - See Documents
| date | description | view/download |
|---|
